贝伐单抗辅助自体角膜缘干细胞移植在复发性翼状胬肉中应用  

The use of Bevacizumab with corneal limbal stern cell autograft for management of recurrent pterygiurn

作　　者：陈乔[1] 刘剑平[1] 聂尚武[1] 伍志琴[1] 

机构地区：[1]湖北省荆州市中心医院眼科,荆州434020

出　　处：《中国实用眼科杂志》2012年第4期483-485,共3页Chinese Journal of Practical Ophthalmology

摘　　要：目的评价贝伐单抗（Avastin）辅助角膜缘干细胞移植治疗复发性翼状胬肉的临床疗效。方法回顾分析36只眼复发性翼状胬肉的临床资料，分为治疗组17只眼行角膜缘干细胞移植术联合贝伐单抗术中球结膜下注射及术后局部点眼，对照组19只眼行角膜缘干细胞移植术。结果随访6个月治疗组与对照组平均视力均较术前明显提高，两者差异无统计学意义（P〉0．05）；平均眼压与术前比较均无显著差异（P〉0．05）；复发率：治疗组元复发，对照组有5例复发，两者差异有统计学意义（P〈0．05）。两组干细胞植片均存活良好，无角膜上皮缺失、糜烂、角膜变薄等并发症发生。结论贝伐单抗联合角膜缘干细胞移植可有效抑制复发性翼状胬肉的复发，未见明显并发症。Objective To evaluate the clinic effect of Bevacizumab with corneal limbal stem cell autograft for management of recurrent pterygium. Methods The retrospective clinical study was performed in 36 eyes with recurrent pterygia, allocated into two groups： Treatment Group （17 eyes） operated by pterygium excision and corneal limbal stem cell autograft with Bevacizumab by intraoperative sub-conjunctival injection and postoperative eyedmps, and Control Group （19 eyes） operated by pterygiurn excision and corneal limbal stern cell autograft without Bevacizumab. Results Follow up of 6 months, the mean visual acuity of Treatment Group and Control Group were improved significantly, the difference was not statistically significant （P 〉0.05）. There was no significant difference （P 〉0.05） in intraocular pressure between preoperative and postoperative. It was significant difference between Treatment Group with no recurrence and Control Group with 5 cases of recurrence （P 〈0.05）. Two groups of stem cell grafts survived well, and there were no complications such as comeal epithelial loss, erosion and corneal thinning. Conclusions Bevacizumab combined with comeal limbal stem cell autograft can effectively inhibit recurrent pterygium recurrence, no obvious complications.

关 键 词：贝伐单抗 角膜缘干细胞移植 翼状胬肉 

分 类 号：R777.33[医药卫生—眼科]